JP2017538104A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017538104A5 JP2017538104A5 JP2017518455A JP2017518455A JP2017538104A5 JP 2017538104 A5 JP2017538104 A5 JP 2017538104A5 JP 2017518455 A JP2017518455 A JP 2017518455A JP 2017518455 A JP2017518455 A JP 2017518455A JP 2017538104 A5 JP2017538104 A5 JP 2017538104A5
- Authority
- JP
- Japan
- Prior art keywords
- configuration
- biomarker
- level
- sample
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 63
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000090 biomarker Substances 0.000 description 61
- 150000001875 compounds Chemical class 0.000 description 37
- 230000001225 therapeutic effect Effects 0.000 description 30
- 239000000523 sample Substances 0.000 description 29
- 206010028980 Neoplasm Diseases 0.000 description 25
- 201000011510 cancer Diseases 0.000 description 25
- 229910052736 halogen Inorganic materials 0.000 description 22
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 239000013074 reference sample Substances 0.000 description 10
- 125000005843 halogen group Chemical group 0.000 description 9
- 239000013078 crystal Substances 0.000 description 8
- 229940002612 prodrug Drugs 0.000 description 8
- 239000000651 prodrug Substances 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 239000012453 solvate Substances 0.000 description 8
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 7
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 7
- 125000005530 alkylenedioxy group Chemical group 0.000 description 7
- 125000004093 cyano group Chemical group *C#N 0.000 description 7
- 125000001072 heteroaryl group Chemical group 0.000 description 7
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 description 6
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 6
- 208000032839 leukemia Diseases 0.000 description 5
- 239000013068 control sample Substances 0.000 description 4
- 108010086507 peptide-chain-release factor 3 Proteins 0.000 description 4
- 102100036816 Eukaryotic peptide chain release factor GTP-binding subunit ERF3A Human genes 0.000 description 3
- 101710151739 Eukaryotic peptide chain release factor GTP-binding subunit ERF3A Proteins 0.000 description 3
- 102100036813 Eukaryotic peptide chain release factor GTP-binding subunit ERF3B Human genes 0.000 description 3
- 102100027377 HBS1-like protein Human genes 0.000 description 3
- 101001009070 Homo sapiens HBS1-like protein Proteins 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 102000015367 CRBN Human genes 0.000 description 2
- 102100023580 Cyclic AMP-dependent transcription factor ATF-4 Human genes 0.000 description 2
- 102100029145 DNA damage-inducible transcript 3 protein Human genes 0.000 description 2
- 101000905743 Homo sapiens Cyclic AMP-dependent transcription factor ATF-4 Proteins 0.000 description 2
- 101000941994 Homo sapiens Protein cereblon Proteins 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 108010057666 Transcription Factor CHOP Proteins 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- DOEVCIHTTTYVCC-UHFFFAOYSA-N 1-(3-chloro-4-methylphenyl)-3-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3h-isoindol-5-yl]methyl]urea Chemical compound C1=C(Cl)C(C)=CC=C1NC(=O)NCC1=CC=C(C(=O)N(C2)C3C(NC(=O)CC3)=O)C2=C1 DOEVCIHTTTYVCC-UHFFFAOYSA-N 0.000 description 1
- -1 ATF3 Proteins 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 102100023583 Cyclic AMP-dependent transcription factor ATF-6 alpha Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 101000905751 Homo sapiens Cyclic AMP-dependent transcription factor ATF-6 alpha Proteins 0.000 description 1
- 101000666295 Homo sapiens X-box-binding protein 1 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102100039064 Interleukin-3 Human genes 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 102100038151 X-box-binding protein 1 Human genes 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 238000009120 supportive therapy Methods 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462061050P | 2014-10-07 | 2014-10-07 | |
| US62/061,050 | 2014-10-07 | ||
| US201462087111P | 2014-12-03 | 2014-12-03 | |
| US62/087,111 | 2014-12-03 | ||
| PCT/US2014/068795 WO2015085172A2 (en) | 2013-12-06 | 2014-12-05 | Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers |
| USPCT/US2014/068795 | 2014-12-05 | ||
| PCT/US2015/054227 WO2016057503A1 (en) | 2014-10-07 | 2015-10-06 | Use of biomarkers for predicting clinical sensitivity to cancer treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017538104A JP2017538104A (ja) | 2017-12-21 |
| JP2017538104A5 true JP2017538104A5 (enExample) | 2018-11-29 |
Family
ID=55653639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017518455A Pending JP2017538104A (ja) | 2014-10-07 | 2015-10-06 | 癌治療に対する臨床的感応性を予測するためのバイオマーカーの使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20180267043A1 (enExample) |
| EP (1) | EP3204008A4 (enExample) |
| JP (1) | JP2017538104A (enExample) |
| WO (1) | WO2016057503A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3737946B1 (en) * | 2018-01-12 | 2024-11-20 | Celgene Corporation | Methods for screening cereblon modifying compounds |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| US12466816B2 (en) | 2019-09-12 | 2025-11-11 | Shanghaitech University | Fused cyclic compound capable of degrading protein and use thereof |
| WO2021179084A1 (en) * | 2020-03-11 | 2021-09-16 | University Health Network | Methods and systems for determining a stem cell type in a glioblastoma |
| EP4277901A1 (en) | 2021-01-13 | 2023-11-22 | Monte Rosa Therapeutics, Inc. | Isoindolinone compounds |
| CN112980882A (zh) * | 2021-03-15 | 2021-06-18 | 上海科技大学 | Crbn基因在构建GSPT1敏感模型中的用途 |
| CN113046391A (zh) * | 2021-03-22 | 2021-06-29 | 上海科技大学 | 一种crbn基因人源化动物肿瘤细胞模型的构建方法和用途 |
| US20240255510A1 (en) * | 2021-05-10 | 2024-08-01 | The Cleveland Clinic Foundation | Salivary metabolites are non-invasive biomarkers of hcc |
| WO2023115065A2 (en) * | 2021-12-17 | 2023-06-22 | Allen Institute | Molecular signatures for cell typing and monitoring immune health |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007086915A2 (en) * | 2005-05-12 | 2007-08-02 | Applied Genomics, Inc. | Reagents and methods for use in cancer diagnosis, classification and therapy |
| US8445198B2 (en) * | 2005-12-01 | 2013-05-21 | Medical Prognosis Institute | Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| MX2009001989A (es) * | 2006-08-30 | 2009-03-09 | Celgene Corp | Compuestos de isoindolina 5-substituidos. |
| US8877780B2 (en) * | 2006-08-30 | 2014-11-04 | Celgene Corporation | 5-substituted isoindoline compounds |
| US20100190656A1 (en) * | 2008-08-08 | 2010-07-29 | Integrated Diagnostics, Inc. | Breast Cancer Specific Markers and Methods of Use |
| SG195613A1 (en) * | 2008-10-29 | 2013-12-30 | Celgene Corp | Isoindoline compounds for use in the treatment of cancer |
| IL288506B2 (en) * | 2012-08-09 | 2023-09-01 | Celgene Corp | Methods for treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoisoindolin-2-yl)piperidine-2,6-dione |
| TW201526897A (zh) * | 2013-04-17 | 2015-07-16 | Signal Pharm Llc | 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法 |
| JP2018525991A (ja) * | 2015-08-12 | 2018-09-13 | セルジーン コーポレイション | 固形腫瘍の治療方法及び免疫調節療法に対する臨床的感度の予測因子としてのバイオマーカーの使用 |
-
2015
- 2015-10-06 WO PCT/US2015/054227 patent/WO2016057503A1/en not_active Ceased
- 2015-10-06 JP JP2017518455A patent/JP2017538104A/ja active Pending
- 2015-10-06 US US15/517,445 patent/US20180267043A1/en not_active Abandoned
- 2015-10-06 EP EP15848775.1A patent/EP3204008A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017538104A5 (enExample) | ||
| JP2021121799A5 (enExample) | ||
| M Dillon et al. | Therapeutic targeting of cancers with loss of PTEN function | |
| Dowless et al. | Abemaciclib is active in preclinical models of ewing sarcoma via multipronged regulation of cell cycle, DNA methylation, and interferon pathway signaling | |
| JP6126069B2 (ja) | 癌の分類および使用法 | |
| US20230107195A1 (en) | Treatment of cancer with smg1-inhibitors | |
| JP6295081B2 (ja) | フラザノベンゾイミダゾールに対する薬物応答のバイオマーカーとしてのアセチル化チューブリンの使用 | |
| US20140135370A1 (en) | Treating cancer with an hsp90 inhibitory compound | |
| JP2016169229A (ja) | ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー | |
| KR20170001962A (ko) | 항 악성 종양제 조성물 | |
| CN117230193A (zh) | 基于c-maf状态的乳腺癌治疗性治疗 | |
| JPWO2020138370A5 (enExample) | ||
| JP6334393B2 (ja) | 薬物応答のバイオマーカーとしてのホスホＡｋｔの使用 | |
| JP6270481B2 (ja) | フラザノベンゾイミダゾールに対する薬物応答のバイオマーカーとしてのｇｌｕ−チューブリンの使用 | |
| CN115175899A (zh) | 使用cdk12/13抑制剂治疗癌症 | |
| US10220091B2 (en) | Combination treatments with sonic hedgehog inhibitors | |
| US20220125777A1 (en) | Combination of a cdk inhibitor and a pim inhibitor | |
| Musi et al. | Tris DBA palladium is an orally available inhibitor of GNAQ mutant uveal melanoma in vivo | |
| AU2017203395A1 (en) | Biomarkers of tumor pharmacodynamic response | |
| JP2019163306A (ja) | ３−［（３−｛［４−（４−モルホリニルメチル）−１ｈ−ピロール−２−イル］メチレン｝−２−オキソ−２，３−ジヒドロ−１ｈ−インドール−５−イル）メチル］−１，３−チアゾリジン−２，４−ジオンとｅｇｆｒチロシンキナーゼ阻害剤との新しい併用 | |
| US12161635B2 (en) | Compositions and methods of treating PIK3CA helical domain mutant cancers | |
| US11672794B2 (en) | Therapeutic targeting of the BAP1 complex in cancer | |
| JP2025525945A (ja) | Ｓｔｋ１１活性または発現が改変されているがんを処置するためのｈｄａｃ阻害剤 | |
| JP2024509887A (ja) | Ｅｐ３００分解剤および神経芽細胞腫におけるその使用 | |
| AU2012208521B9 (en) | Use of stathmin as a biomarker of drug response to furazanobenzimidazoles |